Technical notes
The following is a roundup of peak developments can the biotech space can the final 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE)
Affimed NV (NASDAQ: AFMD) - announced presentation can the AACR Virtual conference II, data can the Bristol-Myers Squibb Co (NYSE: BMY) unit GEnentech's RO7297089 and AFM24 developed from Affimed's sway platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Amicus Therapeutics, Inc. (NASDAQ: FOLD) Ascendis Pharma A/S (NASDAQ: ASND) (presented can the AACR Virtual conference II with pre-clinical data though oncology manufacture candidate)
Atossa Therapeutics Inc (NASDAQ: ATOS)
Burning sway Biotech Ltd (NASDAQ: BNR) (announced entire drill of over-allotment preference can IPO) Cytokinetics, Inc. (NASDAQ: CYTK) Dyadic International, Inc. (NASDAQ: DYAI) Evoke Pharma Inc (NASDAQ: EVOK) (announced FDA approval though inhaled formulation of its gastroparesis drug) Five choice Therapeutics Inc (NASDAQ: FPRX) (moved higher can an analyst upgrade)
GEnMark Diagnostics, Inc (NASDAQ: GNMK)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) - announced eligibility ought accept $10-million milestone payment from Johnson & Johnson's (NYSE: JNJ) Janssen unit though the first EU commercial sales of the subcutaneous formulation of Darzalex, which uses Halozyme's ENHANZE technology Hologic, Inc. (NASDAQ: HOLX)
Horizon Therapeutics PLC (NASDAQ: HZNP)
Immunomedics, Inc. (NASDAQ: IMMU)
MannKind company (NASDAQ: MNKD)
Meridian Bioscience, Inc. (NASDAQ: VIVO) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
